Here are the 8 trades and 3 price-target changes we made during a busy week

Here are the 8 trades and 3 price-target changes we made during a busy week


Traders work during the opening bell at the New York Stock Exchange (NYSE) on Wall Street in New York City on August 16, 2022.

Angela Weiss | AFP | Getty Images

Our portfolio experienced a flurry of adjustments in a week dominated by Nvidia’s (NVDA) quarterly results Wednesday evening and Federal Reserve Chairman Jerome Powell’s Jackson Hole address Friday.

Here’s a day-by-day look at the trades and price-target changes, and what motivated each decision.



Source

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount
Health

Bristol Myers Squibb, Pfizer to sell blockbuster blood thinner Eliquis at 40% discount

Bristol Myers Squibb and Pfizer on Thursday said they will start selling their blockbuster blood thinner, Eliquis, directly to patients at a more than 40% discount. The move comes as the Trump administration ramps up pressure on the pharmaceutical industry to cut drug prices, and threatens to impose sweeping tariffs on pharmaceuticals imported into the […]

Read More
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise
Health

Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise

Boxes of tablets, produced by Novartis AG, sit on a pharmacy counter. Bloomberg | Bloomberg | Getty Images Swiss pharmaceutical firm Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio, as it looks to shift reliance away from its Entresto heart failure therapy. Sales of Kisqali, […]

Read More
Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound
Health

Healthy Returns: Chinese obesity drug emerges as a potential rival to Eli Lilly’s Zepbound

Cr | Istock | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Another potential competitor to blockbuster obesity treatments from Eli Lilly and Novo Nordisk just showed positive data – but this time, […]

Read More